Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Neovasc Inc. (NVCN) Investigation

NEW YORK, NY / ACCESSWIRE / November 2, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neovasc Inc. ("Neovasc" or "the Company") (NASDAQ:NVCN). Investors who purchased Neovasc securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/nvcn.

The investigation concerns whether Neovasc and certain of its officers and/or directors have violated federal securities laws.

On December 20, 2018, Neovasc filed a comprehensive Q-Sub submission to the FDA with all available evidence for its product Neovasc Reducer. On October 28, 2020, the Neovasc revealed that the FDA voted that the Reducer is safe when used as intended, but overwhelmingly voted against issuing a reasonable assurance of effectiveness and on whether the relative benefits outweighed the relative risks. Following this news, Neovasc stock over 17% during intraday trading on October 30, 2020.

If you are aware of any facts relating to this investigation, or purchased Neovasc shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/nvcn. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC